Information Provided By: 
Fly News Breaks for August 31, 2016
ARRY
Aug 31, 2016 | 07:09 EDT
SunTrust analyst Peter Lawson says that the Phase 2 data for Array BioPharma's ARRY-797 was "encouraging." The analyst reports that patients taking the drug showed greater improvement in a 69 minute walk test than those taking approved drugs. He believes that Array's drug can be "part of a $150M-$300M market opportunity." The analyst reiterates his $7 price target and Buy rating on the shares.
News For ARRY From the Last 2 Days
There are no results for your query ARRY
